Related Experiment Video

Updated: Jul 9, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Diagnosis and management of hyperinsulinaemic hypoglycaemia of infancy

Khalid Hussain1

  • 1London Centre for Paediatric Endocrinology and Metabolism, Great Ormond Street Hospital for Children NHS Trust, Institute of Child Health, University College London, London, UK. K.Hussain@ich.ucl.ac.uk

Hormone Research
|December 7, 2007
PubMed

Insights

Hyperinsulinaemic hypoglycaemia, a cause of persistent low blood sugar in infants, requires prompt management to prevent brain damage. Advances in genetics and imaging are improving diagnosis and treatment of congenital hyperinsulinism.

Area of Science:

  • Pediatric Endocrinology
  • Medical Genetics
  • Molecular Biology
  • Nuclear Medicine

Background:

  • Hyperinsulinaemic hypoglycaemia is a critical condition causing persistent low blood sugar in neonates and infants.
  • Early diagnosis and intervention are vital to prevent severe neurological damage and long-term sequelae.
  • Congenital hyperinsulinism presents in transient, prolonged, or persistent forms.

Purpose of the Study:

  • To review current understanding of the mechanisms underlying congenital hyperinsulinism.
  • To highlight recent advances in genetic and diagnostic approaches.
  • To discuss challenges in managing medically unresponsive cases.

Main Methods:

  • Review of molecular biology, genetics, and pancreatic beta-cell physiology.
  • Analysis of mutations in genes associated with unregulated insulin secretion.
  • Evaluation of (18)F-L-dopa positron emission tomography scanning for lesion localization.

Main Results:

  • Mutations in six genes identified, leading to unregulated insulin secretion.
  • (18)F-L-dopa PET scanning shows high sensitivity in differentiating focal from diffuse congenital hyperinsulinism and locating focal lesions.
  • The genetic basis remains unknown in approximately 50% of patients.

Conclusions:

  • Understanding congenital hyperinsulinism mechanisms is advancing through molecular and genetic research.
  • Improved diagnostic tools like (18)F-L-dopa PET scanning are transforming surgical management.
  • Management of medically unresponsive diffuse congenital hyperinsulinism continues to be a significant clinical challenge.

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...